Gene panel testing of 5589 BRCA1/2‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. (9th March 2018)

• Record Type: Journal Article
• Authors: Hauke, Jan; Horvath, Judit; Groß, Eva; Gehrig, Andrea; Honisch, Ellen; Hackmann, Karl; Schmidt, Gunnar; Arnold, Norbert; Faust, Ulrike; Sutter, Christian; Hentschel, Julia; Wang‐Gohrke, Shan; Smogavec, Mateja; Weber, Bernhard H. F.; Weber‐Lassalle, Nana; Weber‐Lassalle, Konstantin; Borde, Julika; Ernst, Corinna; Altmüller, Janine; Volk, Alexander E.; Thiele, Holger; Hübbel, Verena; Nürnberg, Peter; Keupp, Katharina; Versmold, Beatrix; Pohl, Esther; Kubisch, Christian; Grill, Sabine; Paul, Victoria; Herold, Natalie; Lichey, Nadine; Rhiem, Kerstin; Ditsch, Nina; Ruckert, Christian; Wappenschmidt, Barbara; Auber, Bernd; Rump, Andreas; Niederacher, Dieter; Haaf, Thomas; Ramser, Juliane; Dworniczak, Bernd; Engel, Christoph; Meindl, Alfons; Schmutzler, Rita K.; Hahnen, Eric;
• Is Part Of: Cancer medicine. Volume 7:Number 4(2018:Apr.)
• Page Start: 1349
• Page End: 1358
• Publication Date: 2018-03-09
• Subjects: Breast cancer predisposition -- hereditary breast cancer; 616.994005
• DOI: 10.1002/cam4.1376
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: The prevalence of germ line mutations in non‐ BRCA1/2 genes associated with hereditary breast cancer (BC) is low, and the role of some of these genes in BC predisposition and pathogenesis is conflicting. In this study, 5589 consecutive BC index patients negative for pathogenic BRCA1/2 mutations and 2189 female controls were screened for germ line mutations in eight cancer predisposition genes ( ATM, CDH1, CHEK2, NBN, PALB2, RAD51C, RAD51D, and TP53 ). All patients met the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for germ line testing. The highest mutation prevalence was observed in the CHEK2 gene (2.5%), followed by ATM (1.5%) and PALB2 (1.2%). The mutation prevalence in each of the remaining genes was 0.3% or lower. Using Exome Aggregation Consortium control data, we confirm significant associations of heterozygous germ line mutations with BC for ATM (OR: 3.63, 95%CI: 2.67–4.94), CDH1 (OR: 17.04, 95%CI: 3.54–82), CHEK2 (OR: 2.93, 95%CI: 2.29–3.75), PALB2 (OR: 9.53, 95%CI: 6.25–14.51), and TP53 (OR: 7.30, 95%CI: 1.22–43.68). NBN germ line mutations were not significantly associated with BC risk (OR:1.39, 95%CI: 0.73–2.64). Due to their low mutation prevalence, the RAD51C and RAD51D genes require further investigation. Compared with control datasets, predicted damaging rare missense variants were significantly more prevalent in CHEK2 and TP53 in BC index patients. Compared with the overall sample, only TP53 mutation carriers show a significantly younger age at first BC diagnosis. We demonstrate a significant association of deleterious variants in the CHEK2, PALB2, and TP53 genes with bilateral BC. Both, ATM and CHEK2, were negatively associated with triple‐negative breast cancer (TNBC) and estrogen receptor (ER)‐negative tumor phenotypes. A particularly high CHEK2 mutation prevalence (5.2%) was observed in patients with human epidermal growth factor receptor 2 (HER2)‐positive tumors. Abstract : In this case‐control study of well‐characterized breast cancer patients, we confirm ATM, CHEK2, PALB2, CDH1, and TP53 as BC risk genes, no association was observed for NBN . We demonstrate a significant association of deleterious variants in the CHEK2, PALB2, and TP53 genes with bilateral BC and both, ATM and CHEK2, were negatively associated with TNBC and (ER)‐negative tumor phenotypes. Our study confirmed the benefit of multi‐gene testing for risk assessment in BC families while clinical phenotypes associated with non‐ BRCA1/2 gene mutations remain to be determined.